

**COPY OF PAPERS
ORIGINALLY FILED**

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 1 of 1

SEP 18 2002

Compleat if Known

Application Number 10/049,727
 Filing Date 06/25/2002
 First Named Inventor Yahia Gawad
 Group Art Unit 1641
 Examiner Name Gailene Gabel
 Attorney Docket Number 3477-931

RECEIVED

SEP 24 2002

TECH CENTER 1600/291

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No.	U.S. Patent Document Number	Kind Code (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
ck	1	5,629,160		Loskutoff et al.	05/13/1997	
	2	5,472,851		Pussard née Constant et al.	12/05/1995	
	3	5,422,245		Nielsen et al.	06/06/95	
	4	5,352,583		Sakata et al.	10/04/1994	
	5	5,102,787		Sasamata et al.	04/07/1992	
ck	6	4,563,420		Verheijen et al.	01/07/1986	

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T
	7	Friederich et al., <u>Novel Low-Molecular-Weight Inhibitor of PAI-1 (XR3118) Promotes Endogenous Fibrinolysis and Reduces Postthrombolytic Thrombus Growth in Rabbits</u> , Circulation, Vol. 96, No. 3, August 5, 1997, pp. 916-921	
	8	Ohtani et al., T-686, A Novel Inhibitor of Plasminogen Activator Inhibitor-1, Inhibits Thrombosis Without Impairment of Hemostasis in Rats, European Journal of Pharmacology, Vol. 330, 1997, pp. 151-156.	
	9	Nordenhem et al., Plasminogen Activator Inhibitor-1 (PAI-1) Content in Platelets from Healthy Individuals Genotyped for the 4G/5G Polymorphism in the PAI-1 Gene, Scand J. Clin Lab Invest, Vol. 57, 1997, pp. 453-462.	
	10	Lang et al., Calcium-Dependent Stabilization of Type I Plasminogen Activator Inhibitor Within Platelet α -Granules, The Journal of Biological Chemistry, Vol. 271, February 2, 1996, pp. 2754-2761	
	11	Sakata et al., Impaired Fibrinolysis Early After Percutaneous Transluminal Coronary Angioplasty Is Associated With Restenosis, American Heart Journal, Vol. 131, No. 1, January 1996, pp. 1-6	
	12	Eitzman et al., Peptide-Mediated Inactivation of Recombinant and Platelet Plasminogen Activator Inhibitor-1 In Vitro, J. Clin. Invest., Vol. 95, May 1995, pp. 2416-2420	
	13	Nieuwenhuizen et al., An Enzyme Immunoassay for the Simultaneous Determination of Active Type-1 Plasminogen Activator Inhibitor (PAI-1) and PA/PAI-1 Complexes, Blood Coagulation and Fibrinolysis, Vol. 6, 1995, pp. 520-526	
	14	Kurnik, Circadian Variation in the Efficacy of Tissue-Type Plasminogen Activator, Circulation, Vol. 9, No. 5, pp. 1341-1346	
	15	Hara et al., Plasma Plasminogen Activator Inhibitor-1, Tissue Plasminogen Activator and Serum Lipoprotein(a) After Reperfusion Therapy in Acute Myocardial Infarction: Comparison Between Sequential and Director Percutaneous Transluminal Coronary Angioplasty, Cardiology, Vol. 86, 1995, pp. 407-410	
	16	Stringer et al., Plasminogen Activator Inhibitor-1 Released From Activated Platelets Plays a Key Role in Thrombolysis Resistance: Studies With Thrombi Generated in the Chandler Loop, Arteriosclerosis and Thrombosis, Vol. 14, No. 9, September 1994, pp. 1452-1458	
	17	Gram et al., Multicentre Evaluation of Commercial Kit Methods: Plasminogen Activator Inhibitor Activity, Thrombosis and Haemostasis, Vol. 70, No. 5, 1993, pp. 852-857	
	18	Ogawa et al., Difference in Plasminogen Activator Inhibitor Activity Between Non-Q-Wave Infarction and Q-Wave Infarction, International Journal of Cardiology, Vol. 41, 1993, pp. 201-208	
	19	Sakamoto et al., Association of Patency of the Infarct-Related Coronary Artery With Plasma Levels of Plasminogen Activator Inhibitor Activity in Acute Myocardial Infarction, The American Journal of Cardiology, Vol. 70, No. 3, August 1, 1992, pp. 271-276	
	20	Levi et al., Inhibition of Plasminogen Activator Inhibitor-1 Activity Results in Promotion of Endogenous Thrombolysis and Inhibition of Thrombus Extension in Models of Experimental Thrombosis, Circulation, Vol. 85, No. 1, January 1992, pp. 305-312	
	21	Lijnen et al., On the Reversible Interaction of Plasminogen Activator Inhibitor-1 With Tissue-Type Plasminogen Activator and With Urokinase-Type Plasminogen Activator, The Journal of Biological Chemistry, Vol. 266, No. 7, March 5, 1991, pp. 4041-4044	
cf	22	Preissner et al., Identification and Partial Characterization of Platelet Vitronectin: Evidence for Complex Formation With Platelet-Derived Plasminogen Activator Inhibitor-1, Blood, Vol. 74, No. 6, November 1, 1989, pp. 1989-1996	

Examiner Signature

cfostv

Date Considered

1/5/06

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute form 1449A/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		Application Number	10/049,727
(use as many sheets as necessary)		Filing Date	06/25/2002
Street 2 of		First Named Inventor	Yahia Gawad
PATENT & TRADEMARK OFFICE		Group Art Unit	1641
SEP 18 2002		Examiner Name	Gailene Gabel
		Attorney Docket Number	3477-931

23	Wagner et al., <i>Interaction Between Plasminogen Activator Inhibitor Type 1 (PAI-1) Bound to Fibrin and Either Tissue-Type Plasminogen Activator (t-PA) or Urokinase-Type Plasminogen Activator (u-PA)</i> , J. Clin. Invest., Vol. 84, August 1989, pp. 647-655
24	Amiral et al., <i>Measurement of tPA and tPA-PAI-1 Complexes by Elisa, Using Monoclonal Antibodies: Clinical Relevance</i> , Thrombosis Research, Supplement VIII, 1988, pp. 99-113.
25	Francis, Jr. et al., <i>Impaired Fibrinolysis in Coronary Artery Disease</i> , American Heart Journal, Vol. 115, No. 4, April 1988, pp. 776-780
26	Urdén et al., <i>Immunological Relationship Between Plasminogen Activator Inhibitors From Different Sources</i> , Thrombosis and Haemostasis, Vol. 67, No. 1, 1987, pp. 29-34
27	Verheijen et al., <i>Quantitative Analysis of the Composition of Mixtures of On-Chain and Two-Chain Tissue-Type Plasminogen Activator With a Spectrophotometric Method</i> , Thrombosis Research, Vol. 39, 1985, pp. 281-288
28	Hamsten et al., <i>Increased Plasma Levels of Rapid Inhibitor of Tissue Plasminogen Activator in Young Survivors of Myocardial Infarction</i> , The New England Journal of Medicine, Vol. 313, No. 25, December 19, 1985, pp. 1557-1563

RECEIVED

SEP 20 2002

TECH CENTER 1600/2900

Examiner Signature	<i>Chosh</i>	Date Considered	1/6/05
--------------------	--------------	-----------------	--------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.